NGcGM3 ganglioside: a privileged target for cancer vaccines.

Abstract

Active specific immunotherapy is a promising field in cancer research. N-glycolyl (NGc) gangliosides, and particularly NGcGM3, have received attention as a privileged target for cancer therapy. Many clinical trials have been performed with the anti-NGc-containing gangliosides anti-idiotype monoclonal antibody racotumomab (formerly known as 1E10) and the conjugated NGcGM3/VSSP vaccine for immunotherapy of melanoma, breast, and lung cancer. The present paper examines the role of NGc-gangliosides in tumor biology as well as the available preclinical and clinical data on these vaccine products. A brief discussion on the relevance of prioritization of cancer antigens in vaccine development is also included.

• Authors: Luis E Fernandez, Mariano R Gabri, Marcelo D Guthmann, Roberto E Gomez, Silvia Gold, Leonardo Fainboim, Daniel E Gomez, Daniel F Alonso
• Journal: Clinical & developmental immunology (Clin Dev Immunol) Vol. 2010 Pg. 814397 ( 2010) ISSN: 1740-2530 [Electronic] Egypt
• PMID: 21048926 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antibodies, Anti-Idiotypic
• Antibodies, Monoclonal
• Antigens, Neoplasm
• Cancer Vaccines
• G(M3) Ganglioside
• N-glycolylneuraminyllactosylceramide

Topics

• Animals
• Antibodies, Anti-Idiotypic (therapeutic use)
• Antibodies, Monoclonal (therapeutic use)
• Antigens, Neoplasm (immunology)
• Cancer Vaccines
• Clinical Trials as Topic
• G(M3) Ganglioside (analogs & derivatives, immunology)
• Humans
• Immunotherapy
• Neoplasms (immunology, therapy)